Ozempic Receives FDA Approval To Treat Kidney Disease

Core Insights - The FDA has approved Ozempic, a weight loss drug by Novo Nordisk, for treating chronic kidney disease in patients with type 2 diabetes, expanding its potential use and insurance coverage [1][2] - Over 35.5 million Americans suffer from chronic kidney disease, often linked to type 2 diabetes, highlighting the significance of this approval [1] - Novo Nordisk aims to address cardiovascular-kidney-metabolic syndrome through this approval, which affects millions of adults [2] Company Developments - Ozempic and other GLP-1 diabetes drugs are known for their high costs, and they have been included in the Medicare Part D list for price negotiations starting in 2025, with new prices effective in 2027 [3] - Following the FDA approval, Novo Nordisk's stock experienced a decline of 2.65%, closing at $85.19 [4]